In a most recent systematic review on potential prognostic coagulation biomarkers in acute ischemic stroke, PAI‐1 was mentioned as one of the most promising candidates when assessed before the start of reperfusion treatment.27 Interestingly, to date, no study has been published where levels of PAI‐1 during thrombolysis and PAI‐1 4G/5G polymorphism were simultaneously investigated exploring potential associations with the safety and outcome of stroke thrombolysis in humans. The gene discussed is SERPINE1; the disease is stroke disorder.